Clinical trials: Ascites Hepatic
Tense Ascites in Cirrhosis
Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction
The purpose of this study is to determine whether the infusion of albumin 4 gr per liter of ascites removed is as effective as the infusion of albumin 8 gr per liter of ascites removed in the prevention of post-paracentesis…
- Trial name
- NCT00428506
- Testing
- albumin 4 gr/L ascites removed, albumin 8 gr/L ascites removed
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- University of Turin, Italy
Ascites Hepatic
Comparison Between Conventional Angiocatheter Versus New Anchoring Device (KARAHOC) Used for Paracentesis
Comparison of success rate and complication between conventional angiocatheter versus new anchoring device (KARAHOC) used for paracentesis in cirrhotic patients with ascites.
- Trial name
- NCT05578573
- Testing
- KARAHOC device, Angiocatheter
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Sang Gyune Kim
Liver Cirrhosis, Refractory Ascites
Fiber-Optic Navigation During TIPS Creation: A Prospective Pilot Study
Transjugular intrahepatic portosystemic shunt (TIPS) creation is an established minimally invasive treatment for complications of portal hypertension such as refractory ascites and variceal bleeding.
- Conditions
- Liver Cirrhosis, Refractory Ascites, Variceal Bleeding, Portal Hypertension
- Trial name
- FLIGHT (NCT07470515)
- Testing
- Fiber-Optic Navigation System
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Medical University Innsbruck
Liver Cirrhosis, Portal Hypertension
Early TIPS for Ascites Study
The purpose of this study is to demonstrate that TIPS with the GORE® VIATORR® TIPS Endoprosthesis improves transplant-free survival compared to LVP alone in patients who have cirrhosis of the liver with portal hypertension and…
- Conditions
- Liver Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT01236339
- Testing
- TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis, LVP, TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- W.L.Gore & Associates
Hepatic Ascites
Recombinant Human Serum Albumin in Healthy Subjects
This trial adopts a single-center, randomized, double-blind, dose-escalation, placebo-controlled design to evaluate the safety, tolerability, pharmacokinetics, and efficacy of a single administration of recombinant human serum…
- Trial name
- NCT05179265
- Testing
- recombinant human serum albumin, Human serum albumin
- Where
- 2 sites in China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
Ascites Hepatic, Cirrhosis, Liver
Continuous Passive Paracentesis for Intra-abdominal Hypertension
Liver cirrhosis patients in Intensive Care present intra-abdominal hypertension and this is an independent risk factor for increased organ disfunction and mortality.
- Conditions
- Ascites Hepatic, Cirrhosis, Liver, Hypertension, Intraabdominal, Critical Illness
- Trial name
- COPPTRIAHL (NCT04322201)
- Testing
- continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter, Ultrasound-guided intermittent large-volume paracentesis
- Where
- Portugal
- Volunteers
- 60 people
- Sponsor
- Centro Hospitalar de Lisboa Central
Ascites Hepatic
"Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"
This study aims to evaluate beneficial effects of using dapagliflozin in cirrhotic chronic liver disease patients. We hypnotized that the use of dapagliflozin will be associated with fewer need for large volume paracentesis hence…
- Trial name
- NCT07684326
- Testing
- Dapagliflozin
- Where
- Egypt
- Volunteers
- 52 people
- Sponsor
- Beni-Suef University
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Ascites, Liver Cirrhosis
Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis
The purpose of this study is to learn whether a procedure called Proximal Splenic Artery Embolization (PSAE) can lower the need for repeat fluid drainage in adults with cirrhosis and a buildup of fluid in the abdomen (ascites)…
- Conditions
- Ascites, Liver Cirrhosis, Hypertension, Portal
- Trial name
- NCT07755059
- Testing
- Proximal Splenic Artery Embolization
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Cirrhosis With Ascites
Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function
Relative adrenal insufficiency (RAI) is an well known condition in patients with septic shock. Liver failure (including chronic liver failure)and sepsis are both characterized by hyperdynamic circulatory failure (with low…
- Trial name
- AILD (NCT00657306)
- Testing
- hydrocortisone, dextrose solution 5%
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Turin, Italy
Hepatic Ascites
Phase II/III of Recombinant Human Albumin Injection
This study was a Phase II/III multicenter, blinded, and positiveactive-controlled clinical study with seamless adaptive design to evaluate the dose-response relationship, safety, and immunogenicity of recombinant human…
- Trial name
- NCT06411743
- Testing
- Recombinant Human Albumin Injection, Human Albumin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The First Hospital of Jilin University
Cirrhotic Cardiomyopathy, Empagliflozin
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
1. This proposed double-blind placebo controlled randomized controlled trial incorporates recent advances in management of heart failure and portal hypertension using the SGLT-2 inhibitor i.e. EMPAGLIFLOZIN.
- Conditions
- Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors, Cirrhosis
- Trial name
- DICE (NCT07322237)
- Testing
- Empagliflozin + Carvedilol, Carvedilol
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Cirrhosis, Ascites
Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis
Ascites is the most frequent complication of liver cirrhosis and carries a significant worsening of the prognosis. Approximately 10% of patients per year develop refractory ascites because of either the lack of response to…
- Trial name
- ANSWER (NCT01288794)
- Testing
- Diuretics plus human albumin, Diuretics (standard medical treatment)
- Where
- 33 sites in Italy
- Volunteers
- 431 people
- Sponsor
- University of Bologna
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Hepatorenal Syndrome, Liver Cirrhosis
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Patients with advanced cirrhosis of the liver develop kidney problems occasionally. This condition is called Hepatorenal Syndrome, requires hospitalization and frequently results in death.
- Conditions
- Hepatorenal Syndrome, Liver Cirrhosis, Acute Kidney Injury, Ascites Hepatic
- Trial name
- NCT06256432
- Testing
- Ambrisentan, Terlipressin
- Where
- 6 sites in India
- Volunteers
- 54 people
- Sponsor
- Noorik Biopharmaceuticals AG
Cirrhosis, Liver, Liver Fibrosis
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2).
- Conditions
- Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
- Trial name
- NCT05490888
- Testing
- PHIN-214 Subcutaneous injection
- Where
- 9 sites in United States
- Volunteers
- 74 people
- Sponsor
- PharmaIN
Portal Hypertension Related to Cirrhosis, Ascites Hepatic
Effectiveness and Safety of TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hypertension
This Study is a prospective, multi-center, single-arm objective perform an criteria (OPC) study. A 12 months follow-up study on the patients who intend to receive the treatment of cirrhosis and complications of portal…
- Conditions
- Portal Hypertension Related to Cirrhosis, Ascites Hepatic, Variceal Bleeding
- Trial name
- NCT06669806
- Testing
- TIPS Stent Graft
- Where
- China
- Volunteers
- 166 people
- Sponsor
- C. R. Bard
Acute on Chronic Liver Failure
Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.
Ascites is a cardinal and debilitating complication in patients with acute-on-chronic liver failure (ACLF), significantly correlating with disease severity and poor prognosis.
- Trial name
- NCT07422948
- Testing
- Midodrine, Standard Medical Treatment
- Where
- India
- Volunteers
- 113 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Ascites Hepatic
Empagliflozin as a Novel Therapy in Refractory Ascites
The aim of the present study is to investigate the safety, efficacy and cost-effectiveness of empagliflozin, a sodium glucose transporter 2 inhibitor, as an add on therapy to the standard care for refractory ascites in patients…
- Trial name
- NCT05430243
- Testing
- Empagliflozin 10 MG, Diuretics
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Alexandria University
Hepatic Cirrhosis, Ascites
Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis
For hepatic cirrhosis subjects with ascites or lower extremities, to study Pharmacokinetics, pharmacology, and safety of the drug under fasting condition.
- Trial name
- NCT01359462
- Testing
- tolvaptan
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Otsuka Beijing Research Institute